
|Articles|August 4, 2019
Avedro, Inc., company update: Epi-on crosslinking (CXL) and PiXL technology
Author(s)Julianne Mobilian
ICYMI: Here's what's in the 2019 pipeline
Advertisement
Rajesh Rajpal, MD, Chief Medical Officer of Avedro, Inc., provides a company update on Epi-on crosslinking (CXL) and PiXL technology during the 2019 ASCRS conference in San Diego.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


